REVISITING INTERLEUKIN-12 AS A CANCER IMMUNOTHERAPY AGENT

Interleukin-12  antitumor activities are mediated by the activation of T and NK lymphocytes to produce IFN gamma. Systemically, recombinant interleukin-12 has a narrow therapeutic window that favors local delivery, i.e., by gene therapy approaches. Interleukin-12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer.

http://ift.tt/2pi0pkc